Tag: DehydraTECH processed cannabidiol CBD

Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1

Up to 2,178% more CBD delivered into bloodstream* – Up to 1,737% more CBD delivered into brain tissue*
MotherlodeTV
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs. read more

Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET

Lexaria recently announced favorable data on its first animal study, as well as the commencement of its first human clinical study, under its 2021 hypertension R&D program
MotherlodeTV
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that CEO Chris Bunka is presenting at the Benzinga Global Small Cap Conference to be held on May 13-14, 2021. Complimentary investor registration can be accessed through the conference link below. read more